Fusion Antibodies (LON:FAB – Get Free Report) posted its quarterly earnings data on Monday. The company reported GBX (1.20) EPS for the quarter, Digital Look Earnings reports. Fusion Antibodies had a negative net margin of 91.92% and a negative return on equity of 210.32%.
Fusion Antibodies Trading Down 14.5%
Shares of FAB stock traded down GBX 1.65 on Monday, hitting GBX 9.70. 1,942,661 shares of the stock traded hands, compared to its average volume of 415,855. The company has a debt-to-equity ratio of 92.42, a quick ratio of 2.36 and a current ratio of 1.80. The stock has a market capitalization of £12.14 million, a PE ratio of -6.47 and a beta of 1.24. The firm’s 50-day moving average price is GBX 10.89 and its two-hundred day moving average price is GBX 12.20. Fusion Antibodies has a twelve month low of GBX 9.10 and a twelve month high of GBX 21.
About Fusion Antibodies
The Company’s ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion’s proprietary CDRx TM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials.
See Also
- Five stocks we like better than Fusion Antibodies
- SM Energy’s Civitas Merger Is Paying Off, But the Stock’s Run Raises the Bar
- Intel’s Price Hikes Could Put $120 Back in Play
- Blue-Chip Stocks Are Looking Anything But Boring With Dividends and Big 2026 Gains
- Digging for Value: Alpha Metallurgical Resources Insider Buys Big
Receive News & Ratings for Fusion Antibodies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fusion Antibodies and related companies with MarketBeat.com's FREE daily email newsletter.
